HCPro, JustCoding Outpatient - 2016 Issue 20 (May)
Q&A: How do we report codes for new biosimilar products?
May 24th, 2016
Subscribe or sign in to view the full article.
Article Overview
This article addresses reporting considerations for newly released biosimilar products under HCPCS. It is aimed at physicians, pharmacists, and revenue integrity or coding staff who need to track new biosimilar-related identifiers, understand when they become available, and review internal charge capture and claim processes around manufacturer-specific reporting.
Why This Topic Matters
New HCPCS additions can affect how biosimilar products are captured on claims and when services may be reported versus when the code becomes available for use. The article helps readers identify that a new product code and a new modifier were introduced, and that organizations may need to verify internal workflows for accurate manufacturer identification.
What You Will Learn
- How biosimilar product reporting changes may appear in HCPCS updates
- Why timing of code availability can matter for claim reporting processes
- Why organizations may review charge capture and manufacturer-identification workflows
- How related modifier updates can affect biological product reporting
Who Should Read This
- Physicians
- Pharmacists
- Coders
- Billing staff
- Revenue integrity staff
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com